Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.

Acta dermato-venereologica - 12 Apr 2021

Beaudoux Olivia, Ehret Marine, Criquet Emilie, Franceschi Joséphine, Durlach Anne, Oudart Jean-Bapstiste, Visseaux Laetitia, Grange Florent

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Imatinib Mesylate
Share to Melanoma
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proto-Oncogene Proteins c-kit

Source

Open in PubMed Open full text

Identifiers

PMID: 33283249
DOI: 10.2340/00015555-3715
PMCID: PMC9364252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.PMID 33283249Read ↗

V559A and N822I double KIT mutant melanoma with predictable response to imatinib?Semantic proximity Read ↗

KIT mutations in a series of melanomas and their impact on treatment with imatinib.Semantic proximity Read ↗

Complete response in a melanoma patient treated with imatinib.Semantic proximity Read ↗

Major response to imatinib mesylate in KIT-mutated melanoma.Semantic proximity Read ↗

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report.Semantic proximity Read ↗

C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.Semantic proximity Read ↗

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations.Semantic proximity Read ↗

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.Semantic proximity Read ↗

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.Semantic proximity Read ↗

Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.Semantic proximity Read ↗

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor.Semantic proximity Read ↗

Imatinib in c-KIT-mutated metastatic solid tumors: A multicenter trial of Korean Cancer Study Group (UN18-05 Trial).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.